Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 9c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.61), $0.09 worse than the analyst estimate of ($0.52).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• Paylocity acquires AI leave management firm Aidora
• Goldman Sachs Upgrades Amorepacific Corp (090430:KS) (AMRPF) to Buy